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DNA plasmids encoding the open reading frames of canine oral papillomavirus (COPV) nonstructural early genes E1, E2,
or E7 protein were delivered into both oral mucosal and cutaneous epithelial sites in beagle dogs using particle-mediated
immunotherapeutic delivery (PMID) technology. Control dogs were vaccinated with plasmid encoding either hepatitis B virus
surface antigen (HBVs) or COPV L1. Using a prophylactic immunisation protocol, a priming dose of plasmid DNA was followed
by a booster dose 6 weeks later. Four weeks after boost, all dogs were challenged with infectious COPV particles. Following
viral challenge, as shown previously (M. A. Stanley et al., 2001, Vaccine 19, 2783–2792), mucosal papillomas developed in the
negative-control HBVs vaccinated dogs, but all animals in the COPV L1 group were fully protected from disease development.
In the early gene-vaccinated groups five of six in the E1-vaccinated dogs, two of six in E2-vaccinated dogs, and three of six
in the E7-vaccinated beagles developed oral papillomas. Compared to the HBVs negative-control group the oral papillomas
that did develop in the early-gene vaccinated beagles were significantly smaller, shorter in duration, and fewer in number.
Taken together the disease burden was markedly reduced and this was statistically significant. In a second experiment one
group of animals was vaccinated with plasmid encoding the wild-type COPV E1 gene, and a separate group was vaccinated
with plasmid encoding a synthetic codon-optimised COPV E1 gene sequence. None of the codon-optimised E1-vaccinated
animals developed papillomas at any challenge site. However, all animals vaccinated with wild-type E1 had papillomas. These
data suggest that immunisation by PMID with papillomavirus early genes can significantly impact upon subsequent disease
development and that full protection can be achieved using improved vectors encoding codon-optimised gene sequencesKey Words: COPV; vaccine; protection; codon optimised;
INTRODUCTION
The genital tract is the main reservoir of mucosal
human papillomaviruses (HPVs) and is home to more
than 30 HPV genotypes (Brown et al., 1999). These ge-
notypes have received close attention because of the
strong association between infection with specific geni-
tal types, principally HPV 16 and 18, and the subsequent
development of cancer of the uterine cervix in women
(zur Hausen and de Villiers, 1994). Infection with these
HPV types is now regarded as the major risk factor for
the development of cervical cancer, 500,000 new cases
of which are diagnosed each year (Landis et al., 1999).
However benign papillomavirus-associated genital tract
diseases, principally anogenital warts caused predomi-
nantly by HPV-6 and HPV-11, are not trivial infections but
are important in terms of morbidity, economic, and social451; E7; DNA.
costs (Birley, 2001). The development of effective mea-
sures to control these infections is critical, and vaccines
(both prophylactic and therapeutic) are obvious strate-
gies for this.
The natural history of HPV infection is not fully under-
stood because its absolute dependence upon epithelial
differentiation for permissive viral replication makes it
difficult to imitate the life cycle of papillomaviruses in
vitro. Papillomavirus-induced genital lesions are chronic
and persist for months, often years, without evoking an
apparent immune response. However they can also de-
velop and regress in a relatively short period of time
(Handsfield, 1997). This spontaneous regression of gen-
ital warts is a well-recognised phenomenon demonstrat-
ing that the host’s immune system can recognize and
target the virus-infected cells. However, while both hu-
man and animal model studies have shown that regres-
sion correlates with an infiltration of CD4 and CD8 T cellsperhaps emphasizing the importance of antigen load in th
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particular the antigen-specific responses that drive dis-
ease regression are still undefined.
A potential strategy for the development of papilloma-
virus vaccines is to induce cell-mediated immune re-
sponses against nonstructural early papillomavirus pro-
tein. It is known that the E1 and E2 proteins are abso-
lutely required for the replication of viral genomes
(Spalholz et al., 1993); and that E7 (and E6 or E8) proteins
are essential for permissive viral growth (Flores et al.,
2000). These nonstructural proteins are potential targets
of the immune system in the induction of spontaneous
regression of warts, and any therapeutic strategies that
aim to interfere with the expression of these proteins
should, in theory, be able to prevent proliferation of
infected keratinocytes and to promote regression of de-
veloped tumors. Indeed immunisation with E1 or E2
proteins, with or without adjuvant, enhanced significantly
the regression rate of cottontail rabbit papillomavirus-
induced papillomas (Selvakumar et al., 1995). However,
while vaccination with E7 fusion proteins against bovine
papillomavirus-4 resulted in wart rejection (Campo et al.,
1993), no effects with E2 were observed. DNA vaccina-
tion with E1-, E2-, or E7-encoding plasmids by subcuta-
neous or intramuscular route offered no protection in
rabbits against viral challenge (Han et al., 1999), while
vaccination by particle-mediated (gene gun) inoculation
with E6 (Sundaram et al., 1998) generated partial protec-
tion and in combination with E1, E2, and E7 plasmids
(Han et al., 1999) resulted in complete protection against
induced papilloma development in the rabbit model. A
combination of E1 and E2 vaccination by particle-medi-
ated delivery was also protective in the majority of rab-
bits (Han et al., 2000).
We show here that plasmid DNA constructs encoding
canine oral papillomavirus (COPV) early antigens deliv-
ered by particle-mediated immunotherapeutic delivery
(PMID) to the skin and oral mucosa can partially protect
dogs against viral challenge and the development of
virus-induced oral papillomas. We further show that an-
tigen load may be critical as use of codon optimisation of
COPV E1 plasmid results in complete protection against
high-level mucosal challenge with virus.
RESULTS
Plasmid DNA delivery and viral challenge
Delivery of plasmid DNA was undertaken using the
PowderJect XR device under general anesthesia as de-
scribed earlier (Stanley et al., 2001). The dogs recovered
completely from general anesthesia following vaccina-
tion without the occurrence of untoward complications. A
localised reaction was noted on the vaccination sites a
few minutes following delivery of DNA-coated gold par-
ticles. Hyperemia accompanied by slight focal swelling
was observed that lasted for about 2 days. Desquama-
tion was also noted on the second until the fourth day
postvaccination and was more prominent on the cutane-
ous sites. No apparent signs of secondary infection were
observed. On the seventh day postvaccination, all sites
were completely healed with no scar formation. The
entire vaccination procedure was unremarkable with no
major side effects observed; the localised reactions
were comparable in subsequent boosting immunisations
over the same sites. Three weeks following the last
immunisation procedure, all dogs were challenged with
purified COPV virions by the scarification technique onto
five sites on each side of the upper oral mucosa.
In vitro expression
In vitro expression of protein from constructs pCOPVE1w/t,
pCOPVE2w/t, and pCOPVE7w/t is shown in Fig. 1A. Expres-
FIG. 1. (a) Wild-type COPV early gene vaccine expression in 293
cells. (b) Comparison of expression of COPV E1 vaccines.
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sion of both E2 and E7 protein are detectable and of the
expected size (49 and 12 kDa) but E1 (pCOPVE1/w/t) pro-
tein expression could not be detected (expected size, 76
kDa track D, Fig. 1A). Gene products were detected using
an anti-penta-His antibody. However, in 293 cells trans-
fected with the codon-optimised COPV E1 construct
(pCOPVE1c/o), there is a clear E1 band of the expected size
(track D), while again, no E1 protein can be detected from
pCOPVE1/w/t (Fig. 1B). A strong E1 band of slightly larger
size is detectable in track A, which contains a lysate of
insect cells infected with a 5 His-tagged baculovirus clone
of COPV E1, the extra His tag making the protein slightly
larger than the predicted E1 size (76 kDa). In Fig. 1 E1 was
detected using a polyclonal anti-peptide antibody.
Appearance and development of oral papillomas
Following challenge with COPV, the oral mucosa was
monitored at weekly intervals for the appearance of pap-
illomas. The development of papillomas was assessed
by careful measurement of the papilloma diameter (Fig.
2) and photographed for documentation.
The initial appearances of papillomas in the eight
control dogs that received pCMV-HBVs were raised,
smooth, and pale confluent papular lesions confined to
the site of infection. Initial lesions developed 4 to 5
weeks following COPV challenge. As the lesions in-
creased in size with time, the colour became paler and
the consistency turned into a more firm plaque-like
mass. Approximately 1 to 2 weeks later, the outer surface
of most of the lesions became irregularly textured and
then developed into multiple projecting papillae that later
appeared to be similar to a cauliflower mass. The mor-
phology of these matured lesions was maintained for
about 5 weeks before regression began, which lasted
about 2 weeks. Signs of regression were observed as
softening of the lesion, diminution of size, and sloughing
of the mass, leaving a grayish plaque in an erythematous
base. No scarring was noted after complete resolution of
the warts.
Two of the eight dogs in the hepatitis B virus surface
antigens (HBVs) group did not develop oral papillomas.
However, these dogs appeared to have IgG antibodies
against COPV virions detected from prevaccination sera
(Fig. 6). The rest of the dogs developed lesions on almost
all of the 60 challenged sites. Two animals had only nine
lesions, each bringing the total number of lesions to 58
(97%). The average diameter of papillomas was 9 mm,
ranging from 3 to 25 mm, and the average duration
(appearance to resolution) of the lesions was 5–6 weeks
that took place between the fifth and twelfth week fol-
lowing COPV challenge.
The early appearance of papillomas in the E1 group
was different from that seen in the control HBVs group.
These lesions were smaller than the initial observable
papules noted in the HBVs group and were almost un-
detectable because of the similarity of colour as well as
consistency to that of the surrounding oral mucosa. The
lesions were best detected and monitored by touch.
These “micropapular” lesions remained for 1 to 2 weeks
before developing into typical confluent papules as ob-
served in the control group. Most of the lesions did not
progress into florid papillomas (Fig. 2) and in one dog the
observed micropapules regressed completely after 1 to 2
weeks. Only 7 of 44 lesions observed developed into a
typical papilloma. Only one of the six dogs in this group
did not develop an observable papilloma and a total of 44
lesions (73%) of a possible 60 were observed with most
of the papillomas present on the sixth and seventh week
postinfection (Fig. 2). The average diameter of the pap-
illomas was 7.5 mm and the average duration was 3.5
weeks.
Early appearances of warts in the E2 group were
similar to that observed in the E1 group. Of the 16
observed lesions (9 of which started as micropapules),
only 4 developed into a typical cauliflower-like papilloma
(Fig. 2). The total of 16 (27%) of 60 challenged sites had
observable papillomas that were shared over two ani-
mals. The average diameter of the papillomas was 5.8
mm with an average duration of 3 weeks.
As in the E1 and E2 groups most of the lesions in the
E7 group initially appeared as tiny confluent papules.
Forty-five percent (27 of 60) of the challenged sites de-
veloped papillomas spread over three dogs with some of
the lesions starting as micropapules. The average diam-
eter of papillomas was 4 mm and the average duration
was 4 weeks. The observed warts appeared to be at
FIG. 2. Graphical representation of papilloma development following
COPV challenge.
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their maximum size on the ninth and tenth week post-
COPV challenge.
All of the observed papilloma regressed spontane-
ously, leaving no scarring. No signs of oral papilloma
development were observed in the animals immunised
with pCMV-L1-encoding plasmid in either experiment.
Statistical analyses of papilloma development
The mean diameter of papillomas observed in the
control HBVs group was significantly larger than the
mean diameter of papillomas noted in the experimental
groups (E1, E2, and E7) from weeks 4 to 12 (P 0.05, see
Fig. 3). The duration of papillomas (from initial appear-
ance to complete resolution) observed in the experimen-
tal groups was considerably similar albeit significantly
shorter when compared to the HBVs vaccinated dogs
(P  0.05, ANOVA and LSD tests). In terms of number of
papillomas developed in the challenged sites, beagles in
the HBVs group appeared to have the most number of
warts followed by dogs in the E1 group, then by E7
group, and subsequently by E2 immunised beagles.
There was a significant reduction in wart numbers in the
E2 and E7 groups compared to HBVs (P  0.05, ANOVA
and LSD tests).
No animals vaccinated with codon-optimised E1 de-
veloped warts at any site, and again, in this experiment
all of the L1-vaccinated animals were protected. The
animals immunised with wild-type E1 had similar lesions
to those observed previously. All animals had at least
three lesions, although some were only micropapilloma-
tous in morphology. A comparison of total wart numbers,
duration, and sizes are illustrated in Fig. 4.
All beagle dogs in E1, E2, and E7 groups showed an
increase in anti-COPV IgG antibodies following chal-
lenge with COPV particles (Fig. 5). The preexperimental
and prechallenge sera were almost at the same level in
all dogs. This was also true for the E1 c/o group illus-
trating exposure to virions (Fig. 5). In the HBVs group
FIG. 3. Pairwise comparisons. Plot of the difference between predicted mean diameter of warts for HBVs and experimental groups  95%
confidence intervals for this difference. All confidence intervals do not contain zero, implying significant reductions in mean wart size from weeks 4
to 12 for each experimental group (E1, E2, and E7, P  0.05). Adjusting for multiplicity all comparisons significant at P  0.10 (only 3 of 20 seven
comparisons not significant at P  0.05).
FIG. 4. Graphical representation of papilloma development in dogs
immunised with codon-optimised and wild-type COPV E1.
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(Fig. 6), six dogs developed a significant increase in
anti-COPV antibodies following COPV challenge and this
is consistent with seroconversion subsequent to COPV
infection. Two dogs however did not alter the levels of
anti-COPV antibodies following viral challenge from rel-
atively high antibody titers of preexperimental and pre-
challenge sera (Fig. 6). This correlates with a failure to
develop oral papillomas following viral challenge.
Sera from the L1-vaccinated dogs showed an increase
of anti-COPV IgG antibodies following immunisation with
pCMV-L1 DNA (Fig. 5). The modest increase of antibody
titer was relatively similar to that observed in the six
dogs (immunised with the same plasmid) reported in
Stanley et al. (2001). These results may well be corre-
lated with the protection induced by pCMV-L1 immuni-
sation against COPV infection. There was no remarkable
increase of antibody titer following viral challenge, al-
though it can be deduced that there was a slight further
increase in titer post-COPV infection.
DISCUSSION
This study clearly demonstrates the utility of a polynu-
cleotide vaccine in completely preventing the develop-
ment of papillomas by a mucosotrophic papillomavirus
(COPV). We have shown that prophylactic vaccination of
out-bred beagles by PMID using DNA encoding codon
optimised E1 gene completely protected animals against
mucosal challenge with virus. We have illustrated the
importance of antigen load in this protection by direct
comparison of a wild-type E1 vaccine with a codon-
optimised E1 vaccine. Partial protection was induced
following vaccination with early wild-type COPV genes
E2, E7, and E1. Thus 4/6, 3/6, and 1/11 beagles were
completely protected by wild-type E2, E7, and E1 DNA
vaccines, respectively. All animals vaccinated with
codon-optimised E1 (6/6) were completely protected.
The remaining beagles in the experimental groups
showed partial protection in that the papillomas that
FIG. 5. Serum detection of IgG against whole COPV by ELISA. Data were the average absorbance readings (in six dogs immunized with either E1,
E2, or E7 genes and four dogs immunized with L1 gene) of sera taken from Pre, before vaccination; Pre-C, before COPV challenge; C–, weeks after
COPV challenge.
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were generated were significantly smaller and of shorter
duration when compared to control animals vaccinated
with HBVs DNA. There was a hierarchy of size with E2
and E7 immunised animals having smaller lesions than
wt E1 with E2 E7 wt E1 HBVs. However there was
little difference in the duration of lesions from their first
appearance to complete resolution between the E2-, E7-,
and wt E1-vaccinated animals. All early gene vaccinated
animals had papillomas of significantly shorter duration
than the HBVs group.
Polynucleotide vaccines encoding early genes E2, E6,
E7, and E1 delivered by gene gun have been shown to
induce partial protection in the CRPV model when used
individually (Sundaraman et al., 1998), but complete pro-
tection when delivered in combination (Han et al., 1999).
However complete protection following immunisation
with individual early genes, as has been shown in the
present article, has not been achieved in any other study.
Why incomplete protection has been achieved when
wild-type genes are used is a matter for speculation but
the evidence in the present study strongly suggests that
high-level antigen expression and presumably therefore
antigen load is a key factor. It is also possible that codon
optimisation may result in enhanced expression due to
cell-specific codon bias and alteration of codon usage
causes expression in alternative cell types. This cell-
specific regulation of tRNA or synthetase enzymes may
also account for the differential expression levels of viral
antigens in a natural infection. Papillomavirus genes
express at a relatively low level in mammalian cells even
when under the control of strong heterologous promot-
ers since codon usage is, paradoxically, not optimal for
mammalian expression (Zhou et al., 1999; Leder et al.,
2001).
In the present study, in vitro protein expression anal-
ysis showed that protein expression of E7 was easily
detectable, as was E2 expression, but no expression of
E1 could be detected. When E1 was codon optimised,
protein expression was greatly increased and this cor-
related with complete protection in all the vaccinated
animals. Some support for the notion that antigen load is
important comes from the CRPV model using a recom-
binant Listeria moncytogenes CRPV E1 vaccine prepa-
ration (Jensen et al., 1997). In this system E1 expression
in vitro was good and the vaccine resulted in 77% of
animals showing complete protection against virus chal-
lenge.
The mechanisms by which protection was generated
in our study is not known but is unlikely to be antibody
mediated since no significant humoral responses to any
of the relevant early proteins could be detected in any of
the vaccinated animals (data not shown). Similar conclu-
sions have been drawn from the CRPV model in which
early gene specific antibody responses are not detect-
able but PBMC from E1-vaccinated responder animals
were shown to proliferate in response to stimulation with
E1 antigen (Selvakumar et al., 1995; Jensen et al., 1997).
An additional finding of interest in our study was the
development of “micro” papillomas as the earliest detect-
able disease stage in a majority of the early gene vac-
FIG. 6. Serum detection of anti-COPV IgG antibodies using whole COPV by ELISA in eight control dogs vaccinated with plasmid DNA encoding
HBVs antigen. Investigated sera were taken before vaccination (Pre), prior to COPV challenge (Pre-C), 3 and 7 weeks post-COPV challenge (C3 and
C7, respectively). Note that dogs numbered 1 and 4 did not alter the levels of anti-COPV antibodies following viral challenge from relatively high
antibody titres of prevaccination and prechallenge sera.
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cinated beagles. These micropapules were smaller than
the initial lesions seen in the HBVs-vaccinated negative-
control beagles. The micropapules were similar in con-
sistency as well as colour to that of surrounding normal
oral mucosa and lasted for only 1 to 2 weeks. We spec-
ulate that PMID vaccination induced cellular immune
responses that fully protected some early gene vacci-
nated animals but only partially protected others, leading
only to the development of the earliest disease stage
(micropapillomas) only before regressing rapidly. Some
animals however were not protected and developed pap-
illomas of comparable size and duration to those in
control animals. Taken together, PMID vaccination with
wild-type early gene plasmids, while significantly reduc-
ing disease burden, was not fully protective.
The numbers of animals used were similar to those in
other vaccine studies. The method of COPV inoculation
was quite stringent with 97% (58/60) of all challenged
sites developing oral papillomas in the control group
(this discounts the two dogs that had antibodies against
COPV before commencing the experiment). This percent-
age reflected the rigorous challenge technique used and
was higher than in other model systems investigating
papillomavirus vaccines. This reinforces the conclusion
that the resistance to viral challenge seen in the vacci-
nated animals was most likely due to the potency of the
vaccines utilised in this investigation.
This study validates naked plasmid DNA immunisation
with constructs encoding papillomavirus early genes in
the COPV disease model. DNA vaccination with codon-
optimised constructs has proven efficacy in this system.
DNA vaccines have several advantages over other vac-
cine formulations. Advantages include absence of risk of
reversion to pathogenicity and risk of contamination with
adventitious agents, ease of purification and production,
stability, and low costs. These considerations make DNA
immunisation a favorable alternative to whole live-atten-
uated or live-recombinant vector vaccines and killed
pathogen vaccines.
MATERIALS AND METHODS
Expression vectors
The open reading frames for COPV genes E1, E2, and
E7 were amplified directly from the COPV genome (ac-
quired from Deutches Krebsforschungezentrum) by PCR
using PWO polymerase (Roche). Primer sequences are
shown in Table 1. The primers comprise NotI-BamHI
restriction enzyme sites to facilitate cloning into plasmid
vector WRG7077 (PowderJect Vaccines, Inc., Madison,
WI). Clones were designated pCOPVE1w/t, pCOPVE2w/t,
and pCOPVE7w/t. Vector WRG7077, and the other con-
structs used in this study pCMV-L1 and pCMV-HBVs,
have been described previously (Stanley et al., 2001).
The complete open reading frame of COPV E1 was
codon optimised. The computer program Calcgene (Hale
and Thompson, 1998) was used to optimise the native
DNA sequence so that it contained a distribution of
codons that reflected those in highly expressed Esche-
richia coli and mammalian genes. Overlapping oligonu-
cleotides of 40 bases in length (Life Technologies) were
assembled using PCR to make the full-length optimised
gene. The initial 5 primer and 3 primers were designed
to introduce NotI and BamHI cloning sites into the gene.
These sites were then used to clone the optimised gene
into the vector WRG7077 using the NotI-BamHI cloning
sites within the vector. This clone was given the desig-
nation pCOPVE1c/o.
The preparation of cassettes for PMID immunisation
was as previously described (Stanley et al., 2001).
Immunisation procedures and protocol
In the first study three experimental vaccine groups,
each comprising six beagles, were immunised with ei-
ther pCMV-E1w/t, pCMV-E2w/t, or pCMV-E7w/t vaccines
(Fig. 1A). The control groups comprised eight beagles
vaccinated with pCMV-HBVs and a further four beagles
immunised with pCMV-L1. DNA vaccines were delivered
TABLE 1
COPV Primers for E1, E2 and E7 Wild Type Genes
EcoRI NotI
5 PCR primer EcoR1/Not1 E1 CCC TGA CGC GGA CGG AAT TCG CGG CCG CCC ATG GCG GCT AGA AAA GGT ACT GAC T
3 PCR primer BamH1/Xho1/
Asc1 E1
BamHI XhoI AscI
GGA ACT ACT GAG TCT GTA TGA GGA TCC TCG AGG CGC GCC TCG AGG CGT TCC CAT
EcoRI NotI
5 PCR primer EcoR1/Not1 E2 CCC TGA CGC GGA CGG AAT TCG CGG CCG CCC ATG GAG AAA CTC AGC GAG GCC
3 PCR primer BamH1/Xho1/
Asc1 E2
BamHI XhoI AscI
A TTT CGG GGA GGG TTA GAT GAG TTA TAA GGA TCC TCG AGG CGC GCC TCG AGG CGT TCC CAT
EcoRI NotI
5 PCR primer EcoR1/Not1 E7 CCC TGA CGC GGA CGG AAT TCG CGG CCG CCC ATG ATT GGG CAA TCC GCA ACC
BamHI XhoI
3 PCR primer BamH1/Xho1 E7 AAG CTT GAC CAT GGC TAG GGA TCC TCG AGG CGC GCC TCG AGG CGT TCC CAT
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into the upper oral (lip) mucosa, three immunisation sites
on each side, and midventral abdominal skin (three im-
munisation sites on each adjacent side of the linea alba).
In the second experiment an identical regime was used.
The groups comprised five animals that received codon-
optimised COPV E1 (COPVE1c/o), five that received
COPV E1 wild-type (COPVE1w/t), and four that received
COPV L1 (pCMV-L1) (Fig. 1B). Booster vaccinations were
delivered on the sixth week following primary immunisa-
tion and performed in the same manner to primary vac-
cination. Each dog received a total dose of 8 g DNA on
each of the two immunisations. Four weeks after boost-
ing, all dogs were challenged with COPV as previously
described (Stanley et al., 2001). Blood samples were
taken prior to immunisation and at 2 week intervals
thereafter. Following viral challenge, development of
papillomas was monitored, measured, and documented.
Delivery of plasmid DNA by PMID and viral challenge
was performed on dogs under general anesthesia as
previously described (Stanley et al., 2001).
Statistical methods
The mean diameter of papillomas for each dog was
analysed using a mixed model analysis of variance. The
model contained a random effect for dogs (variation
between dogs) and residual error (variability within
dogs). Fixed effects for experimental group, week (4 to
12), and the interaction between experimental group and
week were fitted. Pairwise comparisons of the control
HBVs group to the E1, E2, and E7 groups were made at
each week using Fisher’s LSD test, with adjustments for
multiplicity made using the Benjamini–Hochberg method
(Benjamini and Hochberg, 1995). The number of warts
per dog and average duration of papillomas in weeks
were analysed using a one-way analysis of variance
followed by comparisons of the control HBVs group to
the E1, E2, and E7 groups using Fisher’s LSD test. In
general, results were considered statistically significant
if there was less than 5% (P  0.05) probability of their
occurrence due to chance. Statistical analysis was car-
ried out using SAS (v6.12).
Viral challenge
Animals were subjected to general anesthesia and the
mucosa of the upper lips was lightly scarified using the
end tip of a scalpel blade. Five sites per side of the upper
lip were scarified over an area of approximately 10  10
mm per site. An aliquot of 10 l of purified COPV sus-
pension (approximately 45 ng of COPV L1 protein), iso-
lated and characterised from a clinical case of oral pap-
illomatosis (Nicholls et al., 1999), was applied over each
scarified site using a pipet. The suspension was allowed
to be absorbed for about 3–5 min.
Serum collection from beagles
Blood samples were collected aseptically from either
the jugular vein in the neck or the cephalic vein in the
forearm under gentle manual restraint or under general
anesthesia during vaccination or viral challenge. A 21-
gauge butterfly infusion set connected to a 10- or 20-ml
syringe was used to collect the samples. Ten to fifteen
milliliters of blood was placed into a universal tube
containing 100 mg EDTA per milliliter of sample. The tube
was occasionally swirled to mix on transit to prevent
clotting. Following the centrifugation (Sorvall RC3B) of
blood samples at 2500 g for 10 min, serum was aspi-
rated, aliquoted, and frozen at 70°C for use in enzyme-
linked immunosorbent assay (ELISA).
ELISA
Sera from all beagle dogs were analysed for antibody
response using whole COPV as antigen as previously
described (Stanley et al., 2001). Sera drawn from preim-
munisation (Pre), prechallenge (Pre-C), 3 weeks postviral
challenge (C3), and seven weeks postviral challenge
(C7) bleeds were investigated for the presence of IgG
antibodies against COPV L1 protein. Standard ELISA
technique was performed in this study as previously
described (Stanley et al., 2001).
In vitro expression
Plasmid constructs were transfected into 293 cells in
tandem with reporter GFP constructs to calibrate trans-
fection efficiency. Cell lysates were then electrophoresed
on polyacrylamide gels and Western blotted using stan-
dard techniques. COPV gene products were detected
either using an anti-His antibody (Clontech) or by spe-
cific antipeptide antisera targeting the COPV E1 protein.
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